ReviewOncology letters2025
Evolving role of deubiquitinating enzymes in oral cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cancer affects the mucosal epithelium located within the oral cavity. The prevalence of oral cancer is projected to increase by ~40% by 2040, leading to a subsequent rise in mortality rates. Oral carcinogenesis is complex and multifactorial and numerous signaling pathways are involved in disease development. Deubiquitination is commonly involved in the post-translational process of proteins, and serves a key role in tumorigenesis and cancer development. The present review aims to discuss the function of deubiquitinating enzymes (DUBs) in oral cancer, with a particular focus on oral squamous cell carcinoma (OSCC). The present review also aims to investigate the functional mechanisms, tumorigenic regulation and therapeutic targets of DUBs in OSCC, which may potentially provide a novel theoretical basis for the utilization of DUBs as molecular targets in the treatment of OSCC in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.